1 of 1
Story summary
- President Donald Trump bought up to $680,000 of Eli Lilly stock while his administration promoted GLP-1 policies.
- Ethics disclosures released on May 14 recorded seven Lilly purchases on Trump’s behalf through March, which experts say undermine public trust.
- Lilly entered the Centers for Medicare & Medicaid Services (CMS) $50-a-month Medicare GLP-1 pilot that has a Jan. 8 application deadline.
- Experts noted that a congressional ban on such trading would require new legislation.
